Neuromodulation
Conditions
Brief summary
The Non-invasive Vagus Nerve Stimulation in Patients Undergoing Electrophysiological Study is a single center, pilot, prospective study that aims at evaluating the effects of auricular vagus nerve stimulation (aVNS) on the human cardiac conduction system.
Detailed description
The Non-invasive Vagus Nerve Stimulation in Patients Undergoing Electrophysiological Study is a single center, pilot, prospective study that aims at evaluating the effects of auricular vagus nerve stimulation (aVNS) on the human cardiac conduction system. In this study, we will enroll 10 healthy individuals presenting to the electrophysiology laboratory for an electrophysiological study (EPS). Patients will undergo a standard EPS with 4 catheters (coronary sinus catheter, His catheter, right ventricular catheter, and right atrial catheter). Following the standard EPS, patients will be hooked up a Parasym device to provide transcutaneous electrical stimulation to the auricular branch of the vagus nerve.
Interventions
DEVICEAuricular Vagal Nerve Stimulation
The Parasym device will be placed on the patient's left tragus to provide transcutaneous electrical stimulation to the auricular branch of the vagus nerve.
Sponsors
Northwell Health
University of Oklahoma
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Primary indication for EPS for the evaluation of cardiac conduction system or supraventricular tachycardia.
Exclusion criteria
* Previous EPS with ablation * Previous failed ablation * Known conduction system disease, right or left bundle branch block on EKG * Pregnant women * History of postural orthostatic tachycardia syndrome * Patients who have had prior cervical vagotomy * Patients with skin on the tragus that is broken or cracked * Patients with a history of baseline cardiac disease or atherosclerotic cardiovascular disease, including congestive heart failure (CHF), known severe coronary artery disease or recent myocardial infarction (within 5 years) and patients diagnosed with narrowing of the arteries (carotid atherosclerosis) * Patients with an active implantable medical device, such as a cardiac pacemaker, hearing aid implant, or any implanted metallic, implanted vagus nerve stimulator or electronic device.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Sinus Cycle Length | Pre procedure/procedure | Sinus cycle length (msec) |
| Change in A-H Interval | Pre procedure/procedure | A-H Interval (msec) |
| Change in H-V Interval | Pre procedure/procedure | H-V interval (msec) |
| Change in QRS Duration | Pre procedure/procedure | QRS Duration (msec) |
| Change in QT Duration | Pre procedure/procedure | QT Duration (msec) |
| Change in Sinus Node Recovery Time | Pre procedure/procedure | Sinus Node Recovery Time (msec) |
| Change in AV Node Wenckebach Cycle Length | Pre procedure/procedure | AV Node Wenckebach Cycle Length (msec) |
| Change in AV Node Effective Refractory Period | Pre procedure/procedure | AV Node Effective Refractory Period (ERP) (msec) |
| Change in Atrial Effective Refractory Period | Pre procedure/procedure | Atrial Effective Refractory Period ERP (msec) |
| Change in Right Ventricular Effective Refractory Period ERP | Pre procedure/procedure | Right Ventricular Effective Refractory Period ERP (msec) |
| Change in retrograde block cycle length | Pre procedure/procedure | Retrograde Block Cycle Length (msec) |
| Change in Accessory Pathway Anterograde Effective Refractory Period ERP | Pre procedure/procedure | Accessory Pathway Anterograde Effective Refractory Period (msec) |
| Change in Accessory Pathway Retrograde Effective Refractory Period ERP | Pre procedure/procedure | Accessory Pathway Anterograde Effective Refractory Period (msec) |
| Supraventricular Tachycardia induction | Pre procedure/procedure | Supraventricular Tachycardia induction |
| Supraventricular Tachycardia Termination | Pre procedure/procedure | Supraventricular Tachycardia Termination |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORStavros E Mountantonakis, MD
Northwell Health
Outcome results
None listed